Leandro Ricagni (@leandroricagni) 's Twitter Profile
Leandro Ricagni

@leandroricagni

Médico. Prof. Agdo. Oncologia Radioterápica, Facultad de Medicina. UdelaR.

ID: 2648508627

calendar_today28-06-2014 01:01:02

305 Tweet

217 Followers

583 Following

Daniel E Spratt (@drspratticus) 's Twitter Profile Photo

Kudos to authors doing this on trial. sciencedirect.com/science/articl… Unfortunately and as expected, TULSA = high rates of G3+ side fx, high incontinence rates, high rates of salvage tx in pts who could go on AS and spare it all or get SBRT, which in large phase 3 trials has 10x less

CATEDRA de ONCOLOGÍA CLÍNICA (@catedraoncohc) 's Twitter Profile Photo

Éxito total en las Jornadas Académicas de Uro-Oncología de la Catedra de Oncología Clínica. Muy prestigiosos invitados regionales y referentes nacionales compartimos los avances en cancer de vejiga y prostata. Gracias a todos lo que lo hicieron posible !!!

Éxito total en las Jornadas Académicas de Uro-Oncología de la Catedra de Oncología Clínica. Muy prestigiosos invitados regionales y referentes nacionales compartimos los avances en cancer de vejiga y prostata. Gracias a todos lo que lo hicieron posible !!!
Radioterapia_uy (@radioterapia_uy) 's Twitter Profile Photo

Nota en Subrayado sobre nueva técnica de tratamiento de curso corto para Cáncer de Mama. Se realizó por primera vez en el país en el Hospital de Clínicas. subrayado.com.uy/c944564

Bobby Koneru, MD (@konerumd) 's Twitter Profile Photo

🚨12 Painful Musculoskeletal Conditions That Can Be Treated Effectively with Low Dose Radiation Therapy🚨 As I visit Dr. Seegenschmiedt in Germany this week, I’m amazed at all of the various conditions treated with radiation therapy. Low Dose Radiation Therapy (LDRT) is proving

🚨12 Painful Musculoskeletal Conditions That Can Be Treated Effectively with Low Dose Radiation Therapy🚨

As I visit Dr. Seegenschmiedt in Germany this week, I’m amazed at all of the various conditions treated with radiation therapy. Low Dose Radiation Therapy (LDRT) is proving
fmedoficial (@fmedoficial) 's Twitter Profile Photo

Les invitamos a participar de la semana académica del Hospital de Clínicas Dr. Manuel Quintela Será del 23 al 27 de setiembre, y su tema central la salud mental. Se realizarán actividades y presentarán investigaciones en la temática. ¡Les esperamos!

Matthias Guckenberger (@mat_guc) 's Twitter Profile Photo

New insights into Long-Term Adverse Effects and Complications After Prostate Cancer Treatment, Radiotherapy and Prostatectomy 👉 Both associated with increased risks of AE compared to untreated pts 👉 Cumulative 12-year risks of AE 61% vs 42% after Prostatectomy and Radiotherapy

New insights into Long-Term Adverse Effects and Complications After Prostate Cancer Treatment, Radiotherapy and Prostatectomy
👉 Both associated with increased risks of AE compared to untreated pts
👉 Cumulative 12-year risks of AE 61% vs 42% after Prostatectomy and Radiotherapy
MACA Fundación Pablo Atchugarry (@fpatchugarry) 's Twitter Profile Photo

Mariposa de la Vida llegó a Uruguay ✨ La monumental obra de Pablo Atchugarry, 12 metros de altura y 30 toneladas de acero inoxidable, ahora se encuentra en la rotonda de la Ruta 104. Un regalo invaluable del artista que conecta al país con la fuerza del arte contemporáneo.

Gustavo (@gusviani) 's Twitter Profile Photo

🎙 Randomized Trial 🚨: SBRT vs. RFA for Recurrent Small HCC—Is It Time to Rethink Local Treatment? OncoAlert 🔬 Study Highlights: 📌 Phase III trial, 166 👥 with recurrent HCC (≤5 cm, single lesion). 📌 Randomized to RFA (n=83) or SBRT (n=83) Key Outcomes: ✅ Local

🎙 Randomized Trial 🚨: SBRT vs. RFA for Recurrent Small HCC—Is It Time to Rethink Local Treatment? <a href="/OncoAlert/">OncoAlert</a> 

🔬 Study Highlights:
📌 Phase III trial, 166 👥 with recurrent HCC (≤5 cm, single lesion).
📌 Randomized to RFA (n=83) or SBRT (n=83)

Key Outcomes:
✅ Local
Shankar Siva (@_shankarsiva) 's Twitter Profile Photo

1/ 🧨 OMET trial (GORTEC 2014-04) in oligometastatic HNSCC 👥 N=69, SABR alone vs SABR + chemo + cetuximab 🧪 Key finding: Similar 1-year OS without ⬇️QoL (SABR 55.2% vs chemo-SABR 53.3%). 🏆SABR alone had⬇️toxicity and QoL impact. 📉 Gr 3–4 tox: 8.8% (SABR alone) vs 60% 🧵

1/ 🧨 OMET trial (GORTEC 2014-04) in oligometastatic HNSCC
👥 N=69, SABR alone vs SABR + chemo + cetuximab 
 🧪 Key finding: Similar 1-year OS without ⬇️QoL  (SABR 55.2% vs chemo-SABR 53.3%).
 🏆SABR alone had⬇️toxicity and QoL impact.
 📉 Gr 3–4 tox: 8.8% (SABR alone) vs 60%
🧵
Krishan Jethwa (@krishanjethwa) 's Twitter Profile Photo

🔥❓Is Pre-op Chemoradiation the new SoC for locally advanced gallbladder cancer❓🔥 🚨POLCA-GB🚨 T3-4 or N+ GB cancer 🔍Gem-Cis +- CRT CRT Demonstrated: ✅⬆️OS, at median and with substantial separation at tail of curve (read: dcurability) ✅⬆️PFS ✅⬆️Objective response ✅No

🔥❓Is Pre-op Chemoradiation the new SoC for locally advanced gallbladder cancer❓🔥

🚨POLCA-GB🚨
T3-4 or N+ GB cancer
🔍Gem-Cis +- CRT

CRT Demonstrated:
✅⬆️OS, at median and with substantial separation at tail of curve (read: dcurability)
✅⬆️PFS
✅⬆️Objective response
✅No